Aquestive Therapeutics (NASDAQ:AQST) COO Sells $310,900.00 in Stock

Key Points

• Aquestive Therapeutics COO Cassie Jung sold 62,180 shares of the company's stock for $310,900, reducing her ownership by 18% to 283,346 shares.
• The company's stock recently traded down to $5.01, with a 52-week range between $2.12 and $5.80, and has a 50-day moving average of $4.01.
• Analysts have a consensus rating of "Buy" for Aquestive Therapeutics, with a price target averaging around $10.29 following recent upgrades from multiple firms.

Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) COO Cassie Jung sold 62,180 shares of Aquestive Therapeutics stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $5.00, for a total transaction of $310,900.00. Following the completion of the transaction, the chief operating officer directly owned 283,346 shares of the company's stock, valued at $1,416,730. The trade was a 18.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Aquestive Therapeutics Price Performance

Shares of NASDAQ:AQST traded down $0.41 during trading on Monday, reaching $5.01. 3,306,780 shares of the company's stock traded hands, compared to its average volume of 2,424,860. Aquestive Therapeutics, Inc. has a fifty-two week low of $2.12 and a fifty-two week high of $5.80. The company has a 50-day simple moving average of $4.01 and a 200-day simple moving average of $3.26.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last released its quarterly earnings results on Monday, August 11th. The company reported ($0.14) earnings per share for the quarter, topping analysts' consensus estimates of ($0.18) by $0.04. The business had revenue of $10.00 million during the quarter, compared to analyst estimates of $11.32 million. Aquestive Therapeutics has set its FY 2025 guidance at EPS. As a group, equities analysts expect that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Price T Rowe Associates Inc. MD grew its holdings in shares of Aquestive Therapeutics by 16.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 27,669 shares of the company's stock valued at $99,000 after purchasing an additional 3,821 shares during the period. Northern Trust Corp boosted its holdings in Aquestive Therapeutics by 3.1% in the 4th quarter. Northern Trust Corp now owns 599,812 shares of the company's stock valued at $2,135,000 after purchasing an additional 18,199 shares during the last quarter. Bank of America Corp DE grew its stake in shares of Aquestive Therapeutics by 905.2% in the 4th quarter. Bank of America Corp DE now owns 690,284 shares of the company's stock valued at $2,457,000 after buying an additional 621,614 shares during the period. D. E. Shaw & Co. Inc. increased its holdings in shares of Aquestive Therapeutics by 307.3% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 126,464 shares of the company's stock worth $450,000 after buying an additional 95,418 shares during the last quarter. Finally, Deutsche Bank AG raised its position in shares of Aquestive Therapeutics by 63.9% during the 4th quarter. Deutsche Bank AG now owns 61,989 shares of the company's stock valued at $221,000 after buying an additional 24,170 shares during the period. Hedge funds and other institutional investors own 32.45% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. HC Wainwright reiterated a "buy" rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a research report on Tuesday, June 17th. Oppenheimer lifted their price objective on Aquestive Therapeutics from $7.00 to $8.00 and gave the stock an "outperform" rating in a report on Monday. Lifesci Capital upgraded Aquestive Therapeutics to a "strong-buy" rating in a research note on Wednesday, September 3rd. Finally, Zacks Research upgraded Aquestive Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Wednesday, August 13th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat, Aquestive Therapeutics has a consensus rating of "Buy" and a consensus price target of $10.29.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.